Research Analysts’ Weekly Ratings Changes for Jazz Pharmaceuticals (JAZZ)

A number of firms have modified their ratings and price targets on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) recently:

• 6/12/2026 – Jazz Pharmaceuticals was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/10/2026 – Jazz Pharmaceuticals had its price target raised by Bank of America Corporation from $281.00 to $307.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Jazz Pharmaceuticals had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 6/9/2026 – Jazz Pharmaceuticals was given a new $256.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 5/27/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $234.00 to $253.00. They now have an “overweight” rating on the stock.
• 5/26/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/22/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $232.00 to $301.00. They now have an “overweight” rating on the stock.
• 5/21/2026 – Jazz Pharmaceuticals is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $229.00 price target on the stock.
• 5/21/2026 – Jazz Pharmaceuticals was upgraded by Sanford C. Bernstein to “hold”.
• 5/19/2026 – Jazz Pharmaceuticals was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $307.00 price target on the stock, up from $188.00.
• 5/7/2026 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $245.00 price target on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $239.00 price target on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by TD Cowen from $220.00 to $275.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals was given a new $252.00 price target by Robert W. Baird.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $225.00 to $234.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Royal Bank Of Canada from $195.00 to $258.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $250.00 to $265.00. They now have an “overweight” rating on the stock.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Heather Ann Mcsharry sold 2,000 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the sale, the director directly owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. This represents a 9.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark Douglas Smith sold 1,157 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the sale, the director owned 9,680 shares of the company’s stock, valued at $2,231,724. This trade represents a 10.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,098 shares of company stock worth $2,832,086 over the last ninety days. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.